First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Julie L. Sutcliffe, Ph.D; University of California, Davis
• Collaborator: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Diagnosed with primary or metastatic cancer in one or more of the following locations:

breast, colorectal, lung, pancreas

• Eastern Cooperative Oncology Group (ECOG) performance score of 0-1

• Will sign the Institutional Review Board (IRB)-approved consent form

• Able to remain motionless for up to 30-60 minutes per scan

Exclusion Criteria:

• Creatinine > 2 x upper limit of normal

• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal

• Life expectancy < 3 months (mo)

• Women who are pregnant or breast-feeding

• Patients who cannot undergo PET/compute tomography (CT) scanning

• Lack of availability for follow-up assessments

• Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment